BioSpace News Archive

The shares and pre-funded warrants are being sold at a public offering price of $4.69 per share and $4.68 per pre-funded warrant

PharmaCentra LLC, announces their strategic alliance with the New Jersey CannaBusiness Association (NJCBA).

Genoscience Pharma announces today the extension to France of its first-in-human Phase 1b/2a clinical study using the oral small molecule GNS561 in advanced liver cancers.

Microbiotica announces that it will present at leading microbiome conferences throughout May and June.

Study finds lifetime risk of developing Alzheimer’s varies by age, gender; First estimates that include biomarkers.

NOBLES MEDICAL TECHNOLOGIES II, INC. (NMT2) ANNOUNCES THE PRESENTATION OF ITS ITALIAN CLINICAL DATA PUBLISHED IN EUROINTERVENTION TO BE PRESENTED BY DR. FREDERICO DEMARCO

Kansai University launches the Smart Materials for Advanced and Reliable Therapeutics (KU-SMART) Project.

uniQure N.V. presented data showing successful liver transduction with the AAV5 vector in both non-human primates and humans with pre-existing anti-AAV5 neutralizing antibodies (NABs).

Alivio Therapeutics, an affiliate of PureTech Health plc (LSE: PRTC) developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent Nos. 9,962,339 and 9,974,859, related to the Company’s inflammation-targeting technology platform.

Varian(NYSE: VAR) today announced it received notice from Sirtex Medical Limited (Sirtex) on May 21, 2018 (Pacific daylight time) that the board of directors of Sirtex has now received a binding proposal (CDH Proposal) from CDH Investments.